{"id":904554,"date":"2025-11-03T17:29:34","date_gmt":"2025-11-03T22:29:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vertex-reports-third-quarter-2025-financial-results\/"},"modified":"2025-11-03T17:29:34","modified_gmt":"2025-11-03T22:29:34","slug":"vertex-reports-third-quarter-2025-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vertex-reports-third-quarter-2025-financial-results\/","title":{"rendered":"Vertex Reports Third Quarter 2025 Financial Results"},"content":{"rendered":"

<\/p>\n

Vertex Reports Third Quarter 2025 Financial Results<\/b><\/p>\n

\u2014 Total revenue of $3.08 billion, an 11% increase compared to Q3 2024 \u2014<\/i><\/p>\n

\u2014 Refined full year financial guidance: total revenue guidance now $11.9 to $12.0 billion and total<\/i>combined non-GAAP R&D, AIPR&D, and SG&A expense guidance now $5.0 to $5.1 billion \u2014<\/i><\/p>\n

\u2014 R&D pipeline continues to make progress: five programs in pivotal development and povetacicept Phase 3 IgAN trial full enrollment complete; on track to submit first module of povetacicept IgAN BLA to FDA by end of 2025 \u2014<\/i><\/p>\n

BOSTON–(BUSINESS WIRE<\/a>)–
\nVertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2025, and refined full year 2025 financial guidance.<\/p>\n

\n\u201cVertex delivered strong results across the board in the third quarter, extending our leadership in CF, continuing to build global momentum for CASGEVY, and advancing the launch of JOURNAVX in acute pain,\u201d said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. \u201cWe also delivered strong progress across the R&D pipeline, with completion of enrollment in the Phase 3 study of povetacicept in IgAN, initiation of the Phase 2\/3 study of povetacicept in primary membranous nephropathy, as well as advancement of several programs in research and earlier-stage clinical development. For the remainder of 2025, we are focused on executing the ongoing launches, initiating the povetacicept BLA submission in IgAN for potential U.S. accelerated approval, advancing the pipeline, and preparing for new launches in additional disease areas.\u201d<\/p>\n

Third Quarter 2025 Results<\/span><\/b><\/p>\n

Total revenue<\/b> increased 11% to $3.08 billion compared to the third quarter of 2024, primarily driven by the continued performance of cystic fibrosis (CF) therapies and early contributions from the three ongoing launches. In the U.S., total revenue increased 15% to $1.98 billion due to continued strong CF patient demand, including for ALYFTREK; contributions from CASGEVY and JOURNAVX; and favorable net pricing in CF versus the prior year. Outside the U.S., total revenue increased 4% to $1.10 billion due to solid performance across multiple geographies.<\/p>\n

Combined GAAP and non-GAAP R&D, Acquired IPR&D and SG&A expenses<\/b> were $1.5 billion and $1.3 billion, respectively, compared to $1.3 billion and $1.1 billion, respectively, in the third quarter of 2024. The increases were primarily due to increased R&D investment in support of multiple mid- and late-stage clinical development programs, increased commercial investment to support the launch of JOURNAVX in acute pain, and higher AIPR&D.<\/p>\n

GAAP and non-GAAP effective tax rates<\/b> were 16.6% and 17.6%, respectively, compared to 14.6% and 19.8%, respectively, for the third quarter of 2024. In each of the third quarters of 2025 and 2024, the tax rate benefited from increased R&D tax credits.<\/p>\n

GAAP and non-GAAP net income <\/b>were $1.1 billion and $1.2 billion, respectively, compared to $1.0 billion and $1.1 billion, respectively, for the third quarter of 2024, primarily driven by increased product revenue partially offset by increased operating expenses.<\/p>\n

Cash, cash equivalents, and total marketable securities<\/b> as of September 30, 2025, were $12.0 billion, compared to $11.2 billion as of December 31, 2024. The increase was primarily due to cash flows from operating activities, partially offset by repurchases of Vertex\u2019s common stock pursuant to its share repurchase programs.<\/p>\n

Full Year 2025 Financial Guidance<\/span><\/b><\/p>\n

\nVertex today refined its full year 2025 revenue guidance with total revenue now expected to be $11.9 to $12.0 billion, which assumes continued growth in CF, including the global launch of ALYFTREK; continued uptake of CASGEVY in multiple regions; and early contributions from the U.S. launch of JOURNAVX. Vertex is also revising full year 2025 guidance for combined GAAP and non-GAAP operating expenses. Combined GAAP and non-GAAP R&D, AIPR&D, and SG&A expenses are now expected to be approximately $5.65 to $5.8 billion and $5.0 to $5.1 billion, respectively. This revised outlook accounts for acceleration of povetacicept programs and increased investment in sales and marketing initiatives for JOURNAVX in acute pain. In addition, Vertex lowered its prior non-GAAP effective tax rate guidance of 20.5% to 21.5% to a new range of 17% to 18% to incorporate several one-time tax benefits. These include one-time tax benefits recognized in the third quarter of 2025 from Alpine-related R&D tax credits, as well as anticipated recognition in the fourth quarter of 2025 of previously deferred tax benefits. This financial guidance also includes an immaterial cost impact from tariffs in 2025 based on currently known tariff rates and regulations.<\/p>\n

\nVertex\u2019s financial guidance is summarized below:<\/p>\n\n\n\n\n\n\n\n\n\n\n\n
\n

\n\u00a0<\/p>\n<\/td>\n

\n

Current FY 2025<\/b><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

Previous FY 2025<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

Total revenue<\/b><\/p>\n<\/td>\n

\n

\n$11.9 to $12.0 billion<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n$11.85 to $12.0 billion<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

Combined GAAP R&D, AIPR&D and SG&A expenses *<\/b><\/p>\n<\/td>\n

\n

\n$5.65 to $5.8 billion<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n$5.55 to $5.7 billion<\/p>\n<\/td>\n<\/tr>\n

\n

Combined non-GAAP R&D, AIPR&D and SG&A expenses *<\/b><\/p>\n<\/td>\n

\n

\n$5.0 to $5.1 billion<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n$4.9 to $5.0 billion<\/p>\n<\/td>\n<\/tr>\n

\n

Non-GAAP effective tax rate<\/b><\/p>\n<\/td>\n

\n

\n17% to 18%<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n20.5% to 21.5%<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\n*The difference between the combined GAAP R&D, AIPR&D and SG&A expenses and the combined non-GAAP R&D, AIPR&D and SG&A expenses guidance relates primarily to $650 million to $700 million of stock-based compensation expense.<\/p>\n<\/td>\n<\/tr>\n

\n

\n**Combined GAAP and Non-GAAP R&D, AIPR&D and SG&A expenses guidance includes approximately $100 million of AIPR&D expenses.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

Key Business Highlights<\/span><\/b><\/p>\n

Marketed Products<\/span><\/i><\/b><\/p>\n

Cystic Fibrosis (CF) Portfolio<\/span><\/i><\/b><\/p>\n

Vertex has worked for more than 20 years to discover and develop medicines to treat the underlying cause of CF. Vertex CFTR modulators can treat nearly 95 percent of all people living with CF in core markets and are approved for patients as young as one month old. ALYFTREK, the newest marketed CFTR modulator, is approved in the U.S., the United Kingdom (U.K.), the European Union (EU), Canada, New Zealand, and Switzerland for the treatment of patients 6 years and older. Vertex anticipates that the number of CF patients taking its medicines will continue to grow through new approvals and reimbursement agreements, treatment of younger patients, increased survival, and expansion into additional geographies. Recent progress includes:<\/i><\/p>\n